Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.63 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667346 | 0.87 | CDK4 (0.83) | CDK4MEN1KMT2AKDM4E | |
| SCHEMBL5669236 | 0.78 | CDK4 (0.75) | CDK4MEN1KMT2APARP1KDM4E | |
| SCHEMBL5667036 | 0.77 | CDK4 (1.00) | CDK4MEN1KMT2AKDM4E | |
| SCHEMBL5668012 | 0.77 | CDK4 (0.62) | CDK4MEN1KMT2APARP1 | |
| SCHEMBL13866131 | 0.76 | CDK4 (0.59) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL5666982 | 0.75 | CDK4 (0.47) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL5667973 | 0.72 | CDK4 (0.50) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865880 | 0.71 | CDK4 (0.70) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866006 | 0.68 | CDK4 (0.51) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865907 | 0.66 | CDK4 (0.68) | CDK4CDK1CDK2CDK6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | claimed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7148224-B2 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6914062-B2 | Pyrazinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-05 | — | — | US | disclosed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | CDK4, CDK6, CCNI | CDK4 1/4885CDK1 5/4885CDK2 4/4885 |
| US-20050176719-A1 | Novel pyrazinone derivatives | CDK6, CDK4, CDK16 | CDK4 2/4885CDK1 4/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.